Nobori™ drug eluting stent system: Clinical evidence update

Minerva Cardioangiologica

Volumn 58, Issue 5, 2010, Pages 599-610

  Danzi, G B ^a   Chevalier, B ^b   Ostojic, M ^c   Hamilos, M ^d   Wijns, W ^e  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b Institut Cardiovasculaire   (France)

^c CLINICAL CENTER OF SERBIA   (Serbia)

^d UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^e CARDIOVASCULAR CENTER   (Belgium)

Author keywords

Coronary restenosis; Drug eluting stents; Thrombosis

Indexed keywords

BIOLIMUS A9; CYPHER; EVEROLIMUS; PACLITAXEL; POLYGLACTIN; RAPAMYCIN; STAINLESS STEEL; UNCLASSIFIED DRUG; ZOTAROLIMUS;

CARDIOLOGY; DEGRADATION; DRUG ANALYSIS; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELUTING STENT; DRUG MECHANISM; DRUG RELEASE; HUMAN; IN-STENT RESTENOSIS; LIPOPHILICITY; NONHUMAN; PERIPHERAL CIRCULATION; REVIEW; VASOMOTOR REFLEX;

CLINICAL TRIALS AS TOPIC; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; EQUIPMENT DESIGN; FOLLOW-UP STUDIES; HUMANS; LACTIC ACID; POLYMERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79251488806     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. for the RAVEL Study Group. A Randomized Comparison of a Sirolimus-Eluting Stent with a Standard Stent for Coronary Revascularization. N Eng J Med 2002;346:1773-80.
2. Moses J, Leon M, Popma J, Fitzgerald PJ, Holmes DR, O'Shaughnessy C et al. for the SIRIUS Investigators. Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary Artery. N Engl J Med 2003;349:1315-23.
3. Grube E, Silber S, Hauptmann K, Mueller R, Buellesfeld L, Gerckens U et al. TAXUS I Six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary artery lesions. Circulation 2003;107:38-42.
4. Stone G, Ellis S, Cox D. for the TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. New Engl J Med 2004;350:221-31.
5. Grube E, Hauptman KE, Buellesfeld L. Six-month results of a randomized study to evaluate safety and efficacy of Biolimus A9 eluting stent with a bioerodable polymer coating. EuroInterv 2005;1:53-7.
6. Serruys PW, Ruygrok P, Neuzner J. A randomized comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial. Eurolnterv 2006;2:286-94.
7. Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Münzel T et al. for the ENDEAVOR II Investigators. Randomized, Double-Blind, Multi-center Study of the Endeavor Zotarolimus-Eluting Phosphorylcholine-Encapsulated Stent for Treatment of Native Coronary Artery Lesions - Clinical and Angiographic results of the ENDEAVOR II Trial. Circulation 2006;114:798-806.
8. Kaiser C, Brunner-LaRocca HP, Buser PT, Bonetti PO, Osswald S, Linka A et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitäts Trial (BASKET). Lancet 2005;366:921-9.
9. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-30.
10. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007;369:667-78.
11. Windecker S, Meier B. Late coronary stent thrombosis. Circulation 2007;116;1952-65. (Pubitemid 350287091)
12. Ong AT, McFadden EP, Regar E, de Jaegere PP, van Domburg RT, Serruys PW. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 2005;45:2088-92.
13. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48:193-202.
14. Farb A, Burke AP, Kolodgie FD, Virmani R. Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation 2003;108:1701-6. (Pubitemid 37243657)
15. Nebeker J, Virmani R, Bennett C, Hoffman JM, Samore MH, Alvarez J et al. Hypersensitivity cases associated with drug-eluting coronary stents. J Am Coll Cardiol 2006;47:175-81.
16. Alexis F, Venkatraman SS, Kumar SR, Boey F. In vitro study of release mechanisms of paclitaxel and rapamycin from drug-incorporated biodegradable stent matrices. J Control Rel 2004. 98:67-74.
17. Athanasiou KA, Niederauer GG, Agrawal CM. Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid/polyglycolic acid copolymers. Biomaterials 1996;17:93-102.
18. Ostojic M, Sagic D, Jung R, Zhang YL, Nedeljkovic M, Mangovski L et al. The pharmacokinetics of Biolimus A9 after elution from the Nobori™ stent in patients with coronary artery disease: the NOBORI PK study. Catheter Cardiovasc Interv 2008;72:901-8.
19. Chevalier B, Serruys PW, Silber S. Randomized comparison of Nobori™, biolimus A9-eluting coronary stent with a Taxus®, paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: The Nobori 1 trial. Eurointervention 2007;2:426-4.
20. Chevalier B, Silber S, Park SJ, Garcia E, Schuler G, Suryapranata H et al. Randomized comparison of the Nobori™ Biolimus A9-eluting coronary stent with the Taxus Liberté Paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries. The NOBORI™ 1 Trial-Phase 2. Circ Cardiovasc Intervent 2009;2:188-95.
21. Ostojic M, Sagic D, Beleslin B, Jung R, Perisic Z, Jagic N et al. First clinical comparison of Nobori™-Biolimus A9 eluting stents with Cypher-Sirolimus eluting stents: NOBORI™ CORE nine months angiographic and one year clinical outcomes. EuroInterven 2008;3:574-9.
22. Hamilos M, Ostojic M, Beleslin B, Sagic D, Mangovski L, Stojkovic S et al. Differential effects of drug eluting stents on local endothelium dependent coronary vasomotion. J Am Coll Cardiol 2008;51:2123-9.
23. Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Münzel T et al. randomized, double-blind, multicenter study of the Endeavor Zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II Trial. Circulation 2006;114;798-806.
24. Kandzari D, Leon M, Popma J, Fitzgerald PJ, O'Shaughnessy C, Ball MW et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol 2006;48;2440-7.
25. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J et al. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. Circulation 2009;119:680-6.
26. Morice MC, Colombo A, Meier B, Serruys P, Tamburino C, Guagliumi G et al. Sirolimus- vs Paclitaxel-Eluting Stents in De Novo Coronary Artery Lesions The REALITY Trial: A Randomized Controlled Trial. JAMA 2006;295:895-904.
27. Virmani R. Endothelium and inflammation in the light of coronary drug eluting stents safety assessment [Internet]. Available from http://www. europcronline.com/fo/lecture. (Presentation at EuroPCR 2008) [cited 2010, Sep 23].
28. Vetrovec G, Rizik D, Williard C, Snead D, Piotrovski V, Kopia G. Sirolimus PK Trial: A Pharmacokinetic Study of the Sirolimus-Eluting Bx Velocity Stent in Patients with De Novo. Coronary Lesions. Catheter Cardiovasc Interv 2006;67:32-7.